Sonnet BioTherapeutics Holdings Inc. filings document the regulatory record of a clinical-stage oncology biotechnology company built around the FHAB biologic-drug platform. Its disclosures cover shareholder votes, board elections, executive compensation matters, auditor ratification and other proxy governance subjects.
Material-event filings also describe capital-structure activity, including convertible notes, warrants, private-placement proceeds and Nasdaq continued-listing compliance. Additional 8-K disclosures record employment and compensation arrangements, stockholder meeting results, material agreements, operating and financial results, and risk-related matters tied to the company’s biotechnology business and public-company status.
Sonnet Biotherapeutics Holdings, Inc. filed Amendment No. 1 to its annual report for the year ended September 30, 2025 solely to substitute the correct Report of Independent Registered Public Accounting Firm; all underlying financial statements and disclosures remain unchanged.
The auditor, KPMG LLP, issued an unqualified opinion but emphasized substantial doubt about the company’s ability to continue as a going concern due to recurring losses, negative operating cash flows, and the need for substantial additional financing. A critical audit matter was identified around estimating accrued research and development expenses, including $0.6 million of accrued R&D as of September 30, 2025, reflecting significant judgment in assessing third‑party service provider costs.